Our research team is dedicated to achieving this goal through research efforts that that span basic science, animal studies, and clinical trials. Our team is internationally recognized for its exceptional contributions to improving our understanding of the natural history of type 1 diabetes, developing strategies to prevent and reverse the disease, the use of artificial pancreas technologies, and the use of novel ways to educate patients and providers in diabetes management. In addition, our group is internationally known for expertise and development of novel treatments for Prader-Willi Syndrome.
Current Studies
We offer many studies encompassing a wide range of disciplines and specialties related to the physiology, pathogenesis and treatment of diabetes, as well as its complications, and translation of new knowledge to the clinic and the community.
At Risk T1D Studies:
New T1D Onset Studies:
- Precision ATG with or without verapamil in new onset T1D
- COUR CNP-103
- SafeGuard (SAB 142-201)
- Beta Perserve (EFC 18368)
- GNTI-T1D-HLA
- POLARIS GNTI-Bio 122
- Rezpegaldesleukin TN36 (NKTR-358)
- Immune Function Longitudinal
- Enable Bioscience
General Type 1 Diabetes:
Interested in Learning More?
Please call our main diabetes research line at (352) 294-5760 or email our research manager, Jennifer Hosford.